Halozyme Therapeutics, Inc. HALO

NASDAQ | Biotech | Biotechnology and drug delivery

General analysis — not personal advice.

Signal

BUY

Sentiment

7/10

Strong Q1 execution, reiterated 2026 guidance, and a sizable buyback program improve the near-term return profile and can support EPS/share price, while multiple partner-driven catalysts broaden the future royalty base.

This picture changes. Follow Halozyme Therapeutics, Inc. free — email when the signal or risk changes + a Sunday weekly brief.

Follow Halozyme Therapeutics, Inc. free

Email when the signal or risk changes · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Price & valuation

Last close

USD 103

2026-08-10

1 week

+22.8 %

3 months

+46.5 %

12 months

+60.2 %

From 52w high

-0.5 %

From 52w low

+66.5 %

Market sentiment

Sentiment has improved following an earnings beat and a larger-than-expected buyback program; overall newsflow is positive and focused on royalty growth and an expanding partner catalyst set.

Why BUY?

Consider adding incrementally (e.g., 2–3 tranches) given buyback support and upcoming partner/pipeline events, while staying prepared for partner-news-driven volatility.

We're already tracking Halozyme Therapeutics, Inc. — here are the latest events we've registered

Recent News

On August 6, 2026, Halozyme reported record second-quarter 2026 financial results, with total revenues increasing 48% year-over-year to $481 million. The growth was driven by a 50% surge in royalty revenue from ENHANZE-enabled partner products such as DARZALEX SC and VYVGART Hytrulo. Following the strong quarter, the company raised its full-year 2026 financial guidance for total revenue, royalties, and adjusted EBITDA.

Catalysts

31 Dec 2026 — Share repurchases: at least $400M during 2026

Dilution Risk

Assessment: Low

Create free account — follow 3 companies

What Firelda Watch includes for Halozyme Therapeutics, Inc.

Add the company to your watchlist and get all of this automatically.

Free: 3 companies on your watchlist
Change history and monitoring for every company you follow
Sunday weekly brief — AI roundup of the week's news
Watch/Ultra: same-day email when something material happens

Want to see what a finished analysis looks like?

View a sample analysis

This is a real Firelda analysis. Your analysis of Halozyme Therapeutics, Inc. will be delivered in the same format.

Own Halozyme Therapeutics, Inc.? Create a free account and follow up to 3 companies — change history, weekly brief, and email when the picture changes. Upgrade to Watch for more slots and same-day alerts.

Follow 3 companies free